Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapleural ivosidenib for malignant pleural effusion in lung cancer
ChiCTR2500106355Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivosidenib in malignant pleural effusion (MPE) and bronchial carcinoma, sponsored by Shandong First Medical University. Primary endpoint: Objective response rate (ORR) of malignant pleural effusion. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ivosidenib
03
Conditions
malignant pleural effusion (MPE)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2500106355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106355.